BG64259B1 - Кристална форма на 4-[5-метил-3-фенилизоксазол-4-ил]-бензенсулфонамид - Google Patents
Кристална форма на 4-[5-метил-3-фенилизоксазол-4-ил]-бензенсулфонамид Download PDFInfo
- Publication number
- BG64259B1 BG64259B1 BG103155A BG10315599A BG64259B1 BG 64259 B1 BG64259 B1 BG 64259B1 BG 103155 A BG103155 A BG 103155A BG 10315599 A BG10315599 A BG 10315599A BG 64259 B1 BG64259 B1 BG 64259B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- phenylisoxazol
- benzenesulfonamide
- methyl
- crystalline form
- treatment
- Prior art date
Links
- 0 CCCCC(C)=C[*@@](CN=O)([C@@](*)[C@@](C)C1)C11C(CC)C(C)CC1 Chemical compound CCCCC(C)=C[*@@](CN=O)([C@@](*)[C@@](C)C1)C11C(CC)C(C)CC1 0.000 description 2
Classifications
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L23/00—Details of semiconductor or other solid state devices
- H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
- H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
- H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L23/00—Details of semiconductor or other solid state devices
- H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
- H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
- H01L23/427—Cooling by change of state, e.g. use of heat pipes
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
- H01L2924/0001—Technical content checked by a classifier
- H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Power Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Computer Hardware Design (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2437896P | 1996-08-14 | 1996-08-14 | |
| PCT/US1997/015126 WO1998006708A1 (fr) | 1996-08-14 | 1997-08-12 | Forme cristalline du 4-[5-methyl-3phenylisoxanol-4yl] benzenesulfonamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG103155A BG103155A (en) | 1999-11-30 |
| BG64259B1 true BG64259B1 (bg) | 2004-07-30 |
Family
ID=21820280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103155A BG64259B1 (bg) | 1996-08-14 | 1999-02-08 | Кристална форма на 4-[5-метил-3-фенилизоксазол-4-ил]-бензенсулфонамид |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US6441014B2 (fr) |
| EP (2) | EP0920422B1 (fr) |
| JP (2) | JP3631763B2 (fr) |
| KR (1) | KR100383148B1 (fr) |
| CN (1) | CN1205193C (fr) |
| AP (1) | AP1055A (fr) |
| AR (1) | AR009244A1 (fr) |
| AT (1) | ATE228117T1 (fr) |
| AU (1) | AU722072B2 (fr) |
| BG (1) | BG64259B1 (fr) |
| BR (1) | BR9711151A (fr) |
| CA (1) | CA2264104A1 (fr) |
| CZ (1) | CZ297679B6 (fr) |
| DE (1) | DE69717281T2 (fr) |
| DK (1) | DK0920422T3 (fr) |
| EA (2) | EA003754B1 (fr) |
| EE (1) | EE04237B1 (fr) |
| ES (1) | ES2188971T3 (fr) |
| GE (1) | GEP20022636B (fr) |
| HK (1) | HK1023125A1 (fr) |
| HU (1) | HUP0400923A3 (fr) |
| IL (2) | IL161224A0 (fr) |
| IS (1) | IS1989B (fr) |
| LT (1) | LT4551B (fr) |
| LV (1) | LV12274B (fr) |
| NO (1) | NO312461B1 (fr) |
| NZ (1) | NZ334132A (fr) |
| OA (1) | OA11298A (fr) |
| PL (1) | PL191313B1 (fr) |
| PT (1) | PT920422E (fr) |
| RO (1) | RO120771B1 (fr) |
| RS (1) | RS49671B (fr) |
| SI (1) | SI9720059B (fr) |
| SK (1) | SK283558B6 (fr) |
| TR (1) | TR199900298T2 (fr) |
| TW (1) | TW527350B (fr) |
| UA (1) | UA52684C2 (fr) |
| WO (1) | WO1998006708A1 (fr) |
| ZA (1) | ZA977314B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL191313B1 (pl) * | 1996-08-14 | 2006-04-28 | Searle & Co | Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania |
| NZ333399A (en) | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
| GB9810920D0 (en) * | 1998-05-21 | 1998-07-22 | Merck Sharp & Dohme | Therapeutic use |
| EP1102755B1 (fr) * | 1998-08-07 | 2006-01-04 | Chiron Corporation | Isoxazoles substitues comme modulateurs de recepteur d'oestrogenes |
| AU1398899A (en) * | 1998-11-12 | 2000-06-05 | Algos Pharmaceutical Corporation | Cox-2 inhibitors in combination with centrally acting analgesics |
| CA2364127A1 (fr) * | 1999-03-01 | 2000-09-08 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprenant du tramadol et un medicament inhibiteur selectif de cox-2 |
| ES2234651T3 (es) * | 1999-08-20 | 2005-07-01 | Ortho-Mcneil Pharmaceutical, Inc. | Composicion que comprende una materia de tramadol y un farmaco anticonvulsivo. |
| CA2381895A1 (fr) * | 1999-08-27 | 2001-03-08 | Merck & Co., Inc. | Methode de traitement ou de prevention de la prostatite chronique ou du syndrome de la douleur pelvienne chronique |
| DE10032132A1 (de) * | 2000-07-01 | 2002-01-17 | Lohmann Therapie Syst Lts | Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung |
| CA2455050C (fr) * | 2001-08-15 | 2007-02-20 | Pharmacia & Upjohn Company | Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes |
| US20070072921A1 (en) * | 2002-07-26 | 2007-03-29 | Talley John J | Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide |
| AU2003238668A1 (en) | 2003-04-04 | 2004-10-25 | Hetero Drugs Limited | Novel crystalline forms of valdecoxib |
| PL1745791T3 (pl) | 2003-05-07 | 2013-11-29 | Osteologix As | Leczenie chorób chrząstki/kości za pomocą rozpuszczalnych w wodzie soli strontu |
| US20050182113A1 (en) * | 2003-12-30 | 2005-08-18 | Venkataraman Sundaram | Method for preparing diaryl-substituted isoxazole compounds |
| US20050272787A1 (en) * | 2004-05-19 | 2005-12-08 | Eswaraiah Sajja | Process for preparing crystalline form A of valdecoxib |
| WO2005120499A1 (fr) * | 2004-06-10 | 2005-12-22 | Chandiran Thakashinamoorthy | Forme de valdecoxib adaptee pour des compositions pharmaceutiques |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| ATE368639T1 (de) * | 2004-06-28 | 2007-08-15 | Gruenenthal Gmbh | Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
| KR100591786B1 (ko) | 2004-10-19 | 2006-06-26 | 휴먼팜 주식회사 | 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법 |
| CA2609185A1 (fr) | 2005-05-20 | 2006-11-30 | Ahmed F. Abdel-Magid | Procede de fabrication de derives de sulfamide |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| EP2026790A2 (fr) | 2006-05-19 | 2009-02-25 | Janssen Pharmaceutica, N.V. | Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés |
| MX2011000090A (es) | 2008-06-23 | 2011-03-02 | Janssen Pharmaceutica Nv | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]diox in-2-ilmetil)sulfamida. |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| CN103172583A (zh) * | 2013-03-07 | 2013-06-26 | 深圳市资福药业有限公司 | 一种制备帕瑞昔布的方法 |
| US9375417B2 (en) | 2014-12-04 | 2016-06-28 | Mary's Medicinals LLC | Transdermal cannabinoid formulations |
| US10028904B2 (en) | 2014-12-04 | 2018-07-24 | Wisconsin Alumni Research Foundation | Transdermal cannabinoid formulations |
| CN114441666B (zh) * | 2020-11-05 | 2024-02-27 | 成都百裕制药股份有限公司 | 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法 |
| CA3209491A1 (fr) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| AU699593B2 (en) * | 1995-02-13 | 1998-12-10 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| US5643933A (en) | 1995-06-02 | 1997-07-01 | G. D. Searle & Co. | Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
| PL191313B1 (pl) * | 1996-08-14 | 2006-04-28 | Searle & Co | Postać krystaliczna 4-[5-metylo-3-fenyloizoksazol-4-ilo] benzenosulfonamidu, sposób jej otrzymywania, zawierająca ją kompozycja farmaceutyczna i zastosowania |
| AU2003238668A1 (en) * | 2003-04-04 | 2004-10-25 | Hetero Drugs Limited | Novel crystalline forms of valdecoxib |
| US20050272787A1 (en) * | 2004-05-19 | 2005-12-08 | Eswaraiah Sajja | Process for preparing crystalline form A of valdecoxib |
-
1997
- 1997-08-12 PL PL331607A patent/PL191313B1/pl not_active IP Right Cessation
- 1997-08-12 EP EP97938656A patent/EP0920422B1/fr not_active Expired - Lifetime
- 1997-08-12 EA EA200000891A patent/EA003754B1/ru not_active IP Right Cessation
- 1997-08-12 GE GEAP19974712A patent/GEP20022636B/en unknown
- 1997-08-12 EE EEP199900053A patent/EE04237B1/xx not_active IP Right Cessation
- 1997-08-12 IL IL16122497A patent/IL161224A0/xx unknown
- 1997-08-12 HU HU0400923A patent/HUP0400923A3/hu unknown
- 1997-08-12 EA EA199900200A patent/EA001472B1/ru not_active IP Right Cessation
- 1997-08-12 BR BR9711151A patent/BR9711151A/pt not_active Application Discontinuation
- 1997-08-12 AP APAP/P/1999/001458A patent/AP1055A/en active
- 1997-08-12 DK DK97938656T patent/DK0920422T3/da active
- 1997-08-12 PT PT97938656T patent/PT920422E/pt unknown
- 1997-08-12 TR TR1999/00298T patent/TR199900298T2/xx unknown
- 1997-08-12 SI SI9720059A patent/SI9720059B/sl not_active IP Right Cessation
- 1997-08-12 RO RO99-00176A patent/RO120771B1/ro unknown
- 1997-08-12 SK SK136-99A patent/SK283558B6/sk not_active IP Right Cessation
- 1997-08-12 AT AT97938656T patent/ATE228117T1/de not_active IP Right Cessation
- 1997-08-12 WO PCT/US1997/015126 patent/WO1998006708A1/fr active IP Right Grant
- 1997-08-12 IL IL12825597A patent/IL128255A/en not_active IP Right Cessation
- 1997-08-12 CA CA002264104A patent/CA2264104A1/fr not_active Abandoned
- 1997-08-12 CN CNB971985367A patent/CN1205193C/zh not_active Expired - Fee Related
- 1997-08-12 ES ES97938656T patent/ES2188971T3/es not_active Expired - Lifetime
- 1997-08-12 KR KR10-1999-7001263A patent/KR100383148B1/ko not_active IP Right Cessation
- 1997-08-12 CZ CZ0033499A patent/CZ297679B6/cs not_active IP Right Cessation
- 1997-08-12 NZ NZ334132A patent/NZ334132A/en unknown
- 1997-08-12 AU AU40936/97A patent/AU722072B2/en not_active Ceased
- 1997-08-12 EP EP02025507A patent/EP1283203A1/fr not_active Withdrawn
- 1997-08-12 DE DE69717281T patent/DE69717281T2/de not_active Expired - Fee Related
- 1997-08-12 JP JP51012198A patent/JP3631763B2/ja not_active Expired - Fee Related
- 1997-08-14 ZA ZA977314A patent/ZA977314B/xx unknown
- 1997-08-14 AR ARP970103706A patent/AR009244A1/es not_active Application Discontinuation
- 1997-10-14 TW TW086111783A patent/TW527350B/zh not_active IP Right Cessation
- 1997-12-08 UA UA99031377A patent/UA52684C2/uk unknown
-
1999
- 1999-01-29 IS IS4961A patent/IS1989B/is unknown
- 1999-02-05 NO NO19990541A patent/NO312461B1/no unknown
- 1999-02-08 BG BG103155A patent/BG64259B1/bg unknown
- 1999-02-12 RS YUP-74/99A patent/RS49671B/sr unknown
- 1999-02-12 OA OA9900031A patent/OA11298A/en unknown
- 1999-03-05 LV LVP-99-40A patent/LV12274B/en unknown
- 1999-03-10 LT LT99-024A patent/LT4551B/lt active Protection Beyond IP Right Term
-
2000
- 2000-04-19 HK HK00102376A patent/HK1023125A1/xx not_active IP Right Cessation
- 2000-12-19 US US09/741,213 patent/US6441014B2/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/205,732 patent/US7135489B2/en not_active Expired - Fee Related
-
2004
- 2004-10-15 JP JP2004301644A patent/JP2005015497A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7135489B2 (en) | Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide | |
| EP0946507B1 (fr) | Composes de pyrrolyle substitues destines au traitement de l'inflammation | |
| JP4049307B2 (ja) | Ｃｏｘ−２阻害剤のプロドラッグとしての置換ベンゼンスルホンアミド誘導体 | |
| US5859257A (en) | Isoxazole compounds as cyclooxygenase inhibitors | |
| EP1379513B1 (fr) | Promedicaments de composes inhibiteurs de cyclooxygenase-2 | |
| US20070072921A1 (en) | Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide | |
| MXPA99001526A (en) | Crytalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide | |
| EP1369415A1 (fr) | Dérivés de pyrrole utilisés dans le traitement des inflammations |